Lifeward Ltd. (LFWD) · Oct 8, 2026 · Exec change
CFO hire withdrawn — Aviram will not assume the CFO role; Hexter remains interim
Lifeward’s planned CFO appointment has been withdrawn before the start date. The interim CFO remains, limiting disruption but extending the leadership gap.
Lifeward is trying to scale its commercial ReWalk exoskeleton business while also integrating a newer oral-drug-delivery biotechnology platform, making finance leadership important during a broader transition.
The planned CFO succession is now unresolved. Rami Aviram was due to become CFO on November 1, 2026, but withdrew before joining: “On October 4, 2026, Mr. Aviram informed the Company that he has decided not to join the Company and, accordingly, will not assume the role of Chief Financial Officer.” 〔0〕 That is a fresh negative surprise versus the standing expectation that the announced transition would occur.
The immediate operating disruption appears contained. Josh Hexter remains interim principal financial officer and principal accounting officer until a successor is appointed, with no additional compensation required. 〔1〕 The filing does not disclose a control issue, financial restatement, or change to the business plan; the main consequence is that permanent finance leadership remains unsettled.
Bottom line: This is a modest setback to management continuity, not a change to Lifeward’s operating strategy. It matters mainly because the company must now restart or extend its CFO search while executing a complex commercial and biotech transition.
Appointment of a permanent CFO
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!